Last reviewed · How we verify
Peg-Interferon α
At a glance
| Generic name | Peg-Interferon α |
|---|---|
| Also known as | nucleo(s)tide analogue |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (NA)
- Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon
- Impact of Fatty Liver on Hepatitis B Therapy
- Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients (NA)
- Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） (PHASE4)
- Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy
- HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir. (PHASE4)
- Cemiplimab/Peg-Interferon-α in Advanced CSCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |